Piroxicam-beta-cyclodextrin is a complex of the nonsteroidal antiinflammatory drug (NSAID) piroxicam and an inert cyclic macromolecule, beta-cyclodextrin. In clinical trials in patients with pain or rheumatic diseases arising from other conditions, it was as effective an analgesic as standard piroxicam, and showed a faster onset of action on the first day of treatment. In healthy volunteers short term pharmacodynamic studies showed, piroxicam-beta-cyclodextrin was equivalent to or tended to show less gastrointestinal mucosal toxicity than standard piroxicam, as evaluated by endoscopy and faecal blood loss
Piroxicam-beta-cyclodextrin also known as . . It is of Synthetic origin and belongs to Oxicam. It belongs to Cyclo-oxygenase inhibitor pharmacological group on the basis of mechanism of action. The Molecular Weight of Piroxicam-beta-cyclodextrin is 331.40. Its pKa is 6.3.
Oral absorption of Piroxicam-beta-cyclodextrin is found to be 50% ±50. Plasma protien binding is 99%. and metabolism is reported hepatic. Plasma half life is 30-60 hours.
Piroxicam-beta-cyclodextrin is primarily indicated in conditions like
Acute gout, Acute musculoskeletal disorders, Acute pain, Ankylosing spondylitis, Backache, Dysmenorrhoea, Juvenile chronic arthritis, Migraine, Osteoarthritis, Post operative pain, Rheumatic diseases, and can also be given in adjunctive therapy as an alternative drug of choice in Juvenile rheumatoid arthritis.
No data regarding the interactions of Piroxicam-beta-cyclodextrin was found.
Interference in Pathology
The severe or irreversible adverse effects of Piroxicam-beta-cyclodextrin, which give rise to further complications include Skin reactions, Erythema, Interstitial nephritis.
Piroxicam-beta-cyclodextrin produces potentially life-threatening effects which include GI bleeding, Aplastic Anemia, Renal damage, Peptic ulceration, Purpura, Pemphigus vulagris. which are responsible for the discontinuation of Piroxicam-beta-cyclodextrin therapy.
The signs and symptoms that are produced after the acute overdosage of Piroxicam-beta-cyclodextrin include Nausea, Vomiting, Diarrhea, Convulsions, Coma, Hematuria, Acute renal failure, Dizziness, Headache, Hyperventilation, Rashes, Proteinuria, Hyperreflexia, Tinnitus, Hypoprothrombinemia, GI bleeding, hyper reflexia.
The symptomatic adverse reactions produced by Piroxicam-beta-cyclodextrin are more or less tolerable and if they become severe, they can be treated symptomatically, these include Diarrhea, Skin irritation, Nausea and vomiting, Edema, GI disturbance, Erythema multiforme, Azotemia, bronchoconstriction.
Click on the appropriate strength of the dosage form to view its available brands.
Tabs: 20 mg, 100 mg, 191.3 mg, Caps: 20 mg,
Piroxicam-beta-cyclodextrin's dosage details are as follows:
10 to 20 mg 15 (15) 1 hourly IM For orthopedic surgery administer 40 mg OD for 2 days followed by 20 mg OD
10 to 20 mg 15 (15) 1 hourly PO For orthopedic surgery administer 40 mg OD for 2 days followed by 20 mg OD
Paedriatic Dosage ( 20 Kg. )
No data regarding the Paedriatic dosage details of Piroxicam-beta-cyclodextrin is available.
Neonatal Dosage ( 3 Kg. )
No data regarding the neonatal dosage details of Piroxicam-beta-cyclodextrin is available.
High Risk Groups
Drug should not be given to Pregnant Mothers, patients suffering from Liver Malfunction, Geriatrics, and Neonates.
If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Warning / Precautions
Piroxicam should be used with caution in patients with intrinsic coagulation defects and those on anticoagulant therapy. It should be used with caution in patients with compromised cardiac function, hypertension other condition predisposing to fluid retention. Discontinue drug if skin reaction occurs. It should be used with extra care in the presence of existing controlled infection.
powered by Disqus. comments powered by